McKesson Stock Price, News & Analysis

McKesson Corporation (NYSE: MCK) has announced its fiscal 2023 second-quarter financial results, which are available on their Investor Relations website. A live webcast for investors will be held on November 1 at 4:30 PM ET to discuss these results. McKesson, a leader in healthcare services, is committed to enhancing health outcomes for patients by collaborating with various healthcare stakeholders. For more information on McKesson's financials and upcoming events, please visit their Investor Relations site.

The Board of Directors of McKesson Corporation (NYSE:MCK) declared a regular dividend of 54 cents per share. This dividend is set to be paid on January 3, 2023, to stockholders of record as of December 1, 2022. McKesson, a leader in healthcare services, aims to improve health outcomes by collaborating with various stakeholders in the healthcare ecosystem.

McKesson Corporation (NYSE: MCK) announced an extension of its partnership with CVS Health to distribute pharmaceuticals through June 2027. This partnership, which has lasted over 20 years, aims to improve health outcomes for patients. Additionally, McKesson will release its second-quarter fiscal 2023 earnings results on November 1, 2022, with a conference call scheduled at 4:30 PM Eastern Time. The live webcast will be accessible through McKesson's Investor Relations website.

McKesson Corporation (NYSE:MCK) has announced the acquisition of Rx Savings Solutions for up to $875 million to enhance access, affordability, and adherence solutions for patients. The deal includes a $600 million upfront payment and an additional $275 million contingent on RxSS's performance through 2025. This acquisition aims to strengthen McKesson's ecosystem, leveraging RxSS's technology in reducing prescription costs and enhancing patient medication adherence. The acquisition is expected to close in the second half of Fiscal 2023.

McKesson Corporation (NYSE:MCK) has announced the appointment of LeAnn B. Smith as the new executive vice president and chief human resources officer (CHRO), effective December 1, 2022. She will succeed Tracy L. Faber, who is retiring after 11 years. Smith, who joined McKesson in 2021, will oversee all human resources functions, focusing on talent management, diversity, and organizational change. CEO Brian Tyler expressed confidence in Smith's capabilities, highlighting her extensive experience, including a previous role at Walmart.

McKesson Corporation (NYSE: MCK) announced its fiscal 2023 first-quarter financial results, now available on its Investor Relations website. The company will host a live webcast today, August 3, at 4:30 PM ET to discuss these results. McKesson continues to lead in healthcare services, collaborating with various sectors to enhance care accessibility and affordability. The press release indicates a commitment to delivering insights and services that improve health outcomes across the healthcare spectrum.

On July 22, 2022, McKesson Corporation (NYSE:MCK) declared a regular dividend of $0.54 per share, marking a 15% increase from the previous $0.47. The dividend will be payable on October 3, 2022, to shareholders of record as of September 1, 2022. CEO Brian Tyler emphasized the dividend increase reflects robust cash flow and the company’s confidence in its long-term growth strategy. Notably, this marks the sixth consecutive year of dividend increases for McKesson.

McKesson Corporation (NYSE: MCK) will announce its first quarter fiscal 2023 financial results on August 3, 2022, after market close. The company will conduct a live webcast at 4:30 PM Eastern Time to discuss the results. Investors can access the webcast and related financial documentation on the company’s Investor Relations website. McKesson is committed to improving health outcomes and providing affordable healthcare solutions through partnerships with various stakeholders in the healthcare sector.

McKesson Corporation and HCA Healthcare have announced a joint venture to combine their oncology research arms, US Oncology Research and Sarah Cannon Research Institute, enhancing clinical trial access and drug development. This venture aims to expand oncology research, streamline trial matching for patients, and improve access, particularly for underserved communities. McKesson will hold 51% ownership, with the joint venture expected to close in 2022. Financial details remain undisclosed, and the agreement is subject to regulatory approvals.